TOI (The Oncology Institute) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TOI The Oncology Institute Inc TOI
60 GF Score
Price $6.28
GF Value $2.26
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is The Oncology Institute Net Loan?

Net Loan only applies to banks and insurance companies.

TOI
60GF Score
The Oncology Institute Inc TOI
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is The Oncology Institute (TOI) Overvalued in 2026?

Based on GuruFocus' analysis, The Oncology Institute stock appears to be overvalued. The current stock price of $6.28 is trading 177.9% above its estimated GF Value™ of $2.26. GuruFocus considers The Oncology Institute to be Significantly Overvalued.

Key valuation signals for TOI:

  • Net Loan:
  • GF Value™: $2.26 vs. price of $6.28 (177.9% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the TOI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


The Oncology Institute Business Description

Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
60GF Score

Get the complete analysis for TOI

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.28
Price
$2.26
GF Value